Advertisement

Molecular and Cellular Biochemistry

, Volume 360, Issue 1–2, pp 9–14 | Cite as

Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C

  • Yoshio Aizawa
  • Kai Yohizawa
  • Yuta Aida
  • Haruya Ishiguro
  • Hiroshi Abe
  • Akihito Tsubota
Article

Abstract

The life cycle of the hepatitis C virus (HCV) is closely related to host lipoprotein metabolism. Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection. The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of PEG-IFN/RB therapy, with specific focus on apolipoprotein B-100 (apoB-100) in 148 subjects with chronic HCV G1b infection. Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum apoB-100 and low-density lipoprotein (LDL) cholesterol levels. A significant association was noted between higher levels of apoB-100 (P = 1.1 × 10−3) and LDL cholesterol (P = 0.02) and the subjects having Arg70. A significant association was also observed between subjects carrying the rs8099917 TT responder genotype and higher levels of apoB-100 (P = 6.4 × 10−3) and LDL cholesterol (P = 4.2 × 10−3). Our results suggest that apoB-100 and LDL cholesterol are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic HCV infection. In particular, serum apoB-100 concentration might be an informative marker for judging changes in HCV-associated intracellular lipoprotein metabolism in patients carrying the rs8099917 responder genotype.

Keywords

Hepatitis C virus (HCV) Apolipoprotein B-100 (apoB-100) Pegylated interferon (PEG-IFN) IL28B 

References

  1. 1.
    Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Eng J Med 345:41–52CrossRefGoogle Scholar
  2. 2.
    Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Eng J Med 340:1228–1233CrossRefGoogle Scholar
  3. 3.
    Syed GH, Amako Y, Siddqui A (2010) Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21:33–40PubMedCrossRefGoogle Scholar
  4. 4.
    Popescu CI, Dubuisson J (2009) Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell 102:63–74PubMedCrossRefGoogle Scholar
  5. 5.
    Davis RA, Hui Y (2001) 2000 George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart. Arterioscler Thromb Vasc Biol 21:887–898PubMedCrossRefGoogle Scholar
  6. 6.
    Adiels M, Olofsson SO, Taskinen MR, Boén J (2006) Diabetic dyslipidaemia. Curr Opin Lipidol 17:238–245PubMedCrossRefGoogle Scholar
  7. 7.
    Ye J (2007) Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PloS Pathog 3:1017–1022CrossRefGoogle Scholar
  8. 8.
    Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV (2008) Cellular determinants of hepatitis C virus assembly, maturation, degradation and secretion. J Virol 82:2120–2129PubMedCrossRefGoogle Scholar
  9. 9.
    Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, Ye J (2007) Inhibition of hepatitis virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci 104:5848–5853PubMedCrossRefGoogle Scholar
  10. 10.
    Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analysed in iodixanol density gradient. J Virol 80:2418–2428PubMedCrossRefGoogle Scholar
  11. 11.
    Chang KS, Jiang J, Cai Z, Luo G (2007) Human apolipoprotein E is required for infectivity and production of hepatitis C in cell culture. J Virol 81:13783–13793PubMedCrossRefGoogle Scholar
  12. 12.
    Davis GL, Lindsay KL (2005) Treatment of chronic hepatitis C infection: one step at a time. Lanset Infec Dis 5:524–526CrossRefGoogle Scholar
  13. 13.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965PubMedCrossRefGoogle Scholar
  14. 14.
    Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishim C, Trial Group HALT-C (2006) Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 44:1675–1684PubMedCrossRefGoogle Scholar
  15. 15.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403–410PubMedCrossRefGoogle Scholar
  16. 16.
    Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100–1104PubMedCrossRefGoogle Scholar
  17. 17.
    Ge D, Fella J, Thompson AJ, Simon JS, Shiann KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401PubMedCrossRefGoogle Scholar
  18. 18.
    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yan K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105–1109PubMedCrossRefGoogle Scholar
  19. 19.
    Khan M, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, Hassan S (2010) Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch Virol 155:1735–1753PubMedCrossRefGoogle Scholar
  20. 20.
    Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ (2010) Interferon-lambda genotype and low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51:1904–1911PubMedCrossRefGoogle Scholar
  21. 21.
    Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ (2010) Association between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 52:854–863PubMedCrossRefGoogle Scholar
  22. 22.
    Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, Tsianos E (2008) Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 23:586–591PubMedCrossRefGoogle Scholar
  23. 23.
    Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, Bassendine MF (2009) Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther 15:1282–1290CrossRefGoogle Scholar
  24. 24.
    Angelico F, Francioso S, Del Ben M, Feole K, Carbone M, Pignatelli P, Violi F, Angelico M (2009) Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther 30:444–451PubMedCrossRefGoogle Scholar
  25. 25.
    Backus LI, Boothroyd DB, Phillips BR, Mole LA (2007) Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46:37–47PubMedCrossRefGoogle Scholar
  26. 26.
    Kinoshita M, Kojima M, Matsushima T, Teramoto T (2005) Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 351:115–120PubMedCrossRefGoogle Scholar
  27. 27.
    Roingeard P, Houioux C (2008) Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat 15:157–164PubMedCrossRefGoogle Scholar
  28. 28.
    Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C (2002) Hepatitis C core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16:185–194PubMedCrossRefGoogle Scholar
  29. 29.
    Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH (1992) The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12:1053–1062PubMedCrossRefGoogle Scholar
  30. 30.
    Ank N, West H, Paludan SR (2006) IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 26:373–379PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Yoshio Aizawa
    • 1
  • Kai Yohizawa
    • 1
  • Yuta Aida
    • 1
  • Haruya Ishiguro
    • 1
  • Hiroshi Abe
    • 1
  • Akihito Tsubota
    • 2
  1. 1.Division of Gastroenterology and HepatologyJikei University Aoto HospitalTokyoJapan
  2. 2.Institute of Clinical Medicine and Research (ICMR)Jikei University School of MedicineKashiwaJapan

Personalised recommendations